CLOs on the Move

Nivagen Pharmaceuticals, Inc.

www.nivagen.com

 
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.nivagen.com
  • 3100 Fite Cir Suite 208
    Sacramento, CA USA 95827
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

QLT Inc

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases. QLT`s head office is based in Vancouver, Canada and the company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).

Reditus Laboratories

Reditus Laboratories is a full-service laboratory company. We are committed to providing our client physicians with top-tier, accurate anatomical and clinical pathology services.

Headstrong Project

Headstrong provides cost-free, barrier-free, stigma-free mental health treatment for veterans and their families.

Nostrum Laboratories

Nostrum Laboratories is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cytovia Therapeutics

Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.